AstraZeneca
NEWS
The top COVID-19 story is on the pause of the Johnson & Johnson vaccine in the U.S. over rare blood clots. But it’s not the only news. Here’s a look.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.
In mid-March, more than a dozen countries suspended the deployment of the AstraZeneca-Oxford University vaccine after incidences of blood clots were reported.
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
There was a fair amount of clinical trial news last week. Here’s a look.
The announcement by the NIAID, a part of the National Institutes of Health (NIH), is very unusual.
JOBS
IN THE PRESS